Combined modality therapy of resectable high risk XXXX .

@entity1 @entity137 @entity5 @entity1161 @entity1138 @entity20787
Aim of this phase I-II study was to evaluate the efficacy of preoperative concomitant radiochemotherapy in resectable high risk (TNM stage: II and III) @entity5 , 64 @entity1 entered the study: 37 had @entity5 . 50 @entity1 were clinically staged as stage III (Dukes C) and 14 as stage II (Dukes B). Treatment protocol included bolus @entity1138 at the dose of 10 mg/m2 on day 1 and 5FU continuous infusion at the daily dose of 1000 mg/m2 on day 1, 2, 3, 4. Concomitant external radiotherapy up to a dose of 3780 cGy was delivered at the daily dose of 180 cGy. Surgery was performed 4 to 5 weeks after @entity1161 ( @entity1161 ). Before surgery all @entity1 were clinically restaged to evaluate the response to concomitant radiochemotherapy. Treatment compliance was 97%. @entity137 was 27% prevalently shown as bone marrow depletion and @entity20787 . In 37 @entity1 (61%) there was 50% reduction (partial response) of neoplastic volume. In 5 @entity1 (8%) no neoplastic cells were evidenced in the surgical specimen on histology (complete response). The distance between the lower margin of the @entity5 and the internal anal orifice increased in 72% of cases. Postoperative morbidity was 28%. The incidence of anastomotic dehiscences was 8.7% over 46 anterior resections. Postoperative mortality was nil. Definitive staging evidenced 24 @entity1 (39%) stage I or with no evidence of @entity5 . The incidence of local recurrence was 5% and that of distant metastasis 8%.
